 
 
 
Protocol: I8R-MC-IGBO(a)  
 
 
An Open -Label, Multi- Center, Single- Dose Study to Assess the 
Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of 
Nasal Glucagon in Pediatric Patients With Type 1 Diabetes Aged 1 to 
<4 Years   
 
 
[STUDY_ID_REMOVED]  
 
 
Approval Date: 28- Jul-2022  
CONFIDENTIAL  I8R-MC-IGBO (a) 
  1 Title Page  
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators.  It is the property of 
Eli Lilly and  Company or its subsidiaries and should not be copi[INVESTIGATOR_729981] (LY900018) , unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsi diaries.  
 
Note to Regulatory Authorities:  This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure.  Eli Lilly and Company requests consultation regarding release/redaction prior to any pu blic release.  
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
 
Protocol Title:  An Open -Label, Multi -Center, Single -Dose Study to Assess the Safety, Tolerability, 
Pharmacodynamics, and Pharmacokinetics of Nasal Glucagon in Pediatric Patients with Type 1 
Diabetes  Aged 1  to <4 years  
Protocol Number:  I8R-MC-IGBO  
Amendment Number: a 
Compound : Nasal glucagon  
Study Phase: 1 
Short Title:  A Single -Dose Study to Assess Nasal Glucagon in Pediatric Patients with Type 1 
Diabetes  aged 1  to <4 years  
Sponsor Name:  [CONTACT_11028]:  Indianapolis, Indiana , [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Number(s) : IND 110674 , NDA 210134  
Approval Date:  Protocol  Amendment (a) Electronically  Signed and  Approved  by [CONTACT_10937].  
Document ID:  VV-CLIN -069838  
  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  [ADDRESS_997032] Information will be provided separately . 
 
  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  3 Protocol Amendment Summary of Changes Table  
 
DOCUMENT HISTORY  
Document  Date  
Original Protocol  19-Mar-2021  
Amendment [a]  
This amendment is considered to be nonsubstantial.  
Overall Rationale for the Amendment:  
To revise  the existing inclusion criterion for hemoglobin A1c (HbA1c) to align with the  observed 
distribution at study sites so that the study can consider a wider patient population as potential 
study participants without impacting study participants’ safety and study data integrity.  
Additional clarifications  were made as outlined in the ta ble below . 
 
Section # and 
Name  [CONTACT_9353] 1.1. 
Synopsis  and 
Section 3. 
Objectives and 
Endpoints  In the first secondary endpoint, 
added predose BG in parenthesis , 
deleted plasma from parenthesis , 
and replaced plasma with blood . To provide additional information  and 
clarification  
Section 1.3. 
Schedule of 
Activities 
(SoA)  Included SC injection of insulin 
as an option for MDI users  Added for consistency with Section 
4.1.4.  
Section 3. 
Objectives and 
Endpoints  In the exploratory endpoint, 
added predose BG in parenthesis  
and replaced plasma with blood  To provide additional information  and 
clarification  
Section 4.1.4. 
Day 1: 
Predose  Included SC injection of insulin 
as an option for MDI users  Added for flexibility in tre atment options 
for MDI users  
Section 4.1.5. 
Day 1: Dosing  NG will be administered within 5 
minutes of baseline BG 
measurement changed as predose 
BG measurement  Correction to state that NG 
administration to be done within 5 
minutes of predose BG rather than from 
baseline BG  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  4 Section # and 
Name  [CONTACT_9353] 5.1. 
Inclusion 
Criteria  In inclusion criterion 4, increased 
the HbA1c level from ≤9.0 to 
≤9.5%  To revise the existing inclusion criterion 
for HbA1c to align with the observed 
distribution at study sites so that the 
study can consider a wider patient 
population as potential study participants 
without impacting study participants’ 
safety and study data integrity.  
  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  5 Table of Contents  
1. Protocol  Summary  ................................ ................................ ................................ .......... 8 
1.1. Synopsis  ................................ ................................ ................................ ............................ 8 
1.2. Schema  ................................ ................................ ................................ .............................. 9 
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 10 
2. Introduction  ................................ ................................ ................................ ................... 16 
2.1. Study Rationale  ................................ ................................ ................................ ............... 16 
2.2. Background  ................................ ................................ ................................ ..................... 16 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 16 
2.3.1.  Risk Assessment  ................................ ................................ ................................ ............. 17 
2.3.2.  Benefit Assessment  ................................ ................................ ................................ ......... 19 
2.3.3.  Overall Benefit: Risk Conclusion  ................................ ................................ ................... 19 
3. Objectives and Endpoints  ................................ ................................ ............................ 21 
4. Study Design  ................................ ................................ ................................ .................. 22 
4.1. Overall  Design  ................................ ................................ ................................ ................ 22 
4.1.1.  Screening ................................ ................................ ................................ ......................... 22 
4.1.2.  Predosing -Visit Telephone Reminder  ................................ ................................ ............. 22 
4.1.3.  Day 1: Call/Text on Morning of Dosing  ................................ ................................ ......... 23 
4.1.4.  Day 1: Predose  ................................ ................................ ................................ ................ 23 
4.1.5.  Day 1: Dosing  ................................ ................................ ................................ ................. 24 
4.1.6.  Day 1: Postdose ................................ ................................ ................................ ............... 24 
4.1.7.  Follow -up ................................ ................................ ................................ ........................ 24 
4.1.8.  Rescheduling Visits  ................................ ................................ ................................ ........ 24 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 25 
4.3. Justification for Dose  ................................ ................................ ................................ ......25 
4.4. End of Study Definition  ................................ ................................ ................................ ..26 
5. Study Population  ................................ ................................ ................................ ........... 27 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 27 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 28 
5.2.1.  Additional Exclusion Criteria Prior to Dosing Visit (Day 1)  ................................ ......... 29 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .29 
5.3.1.  Meals and Dietary Restrictions  ................................ ................................ ....................... 29 
5.4. Screen Failures  ................................ ................................ ................................ ................ 30 
6. Study Intervention  ................................ ................................ ................................ ........ 31 
6.1. Study Intervention Administered  ................................ ................................ .................... 31 
6.1.1.  Administration Details  ................................ ................................ ................................ ....31 
6.2. Preparation/Handling/Storage/Accountability  ................................ ................................ 31 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 32 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 32 
6.5. Concomitant Therapy  ................................ ................................ ................................ .....32 
6.6. Dose Modification  ................................ ................................ ................................ .......... 32 
6.7. Intervention after the End of the Study  ................................ ................................ ........... 32 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  6 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 33 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 33 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ [ADDRESS_997033] Complaints  ................................ ................................ ................................ ......... 38 
8.4. Treatment of Overdose  ................................ ................................ ................................ ...39 
8.5. Pharmacokinetics  ................................ ................................ ................................ ............ 39 
8.5.1.  Bioanalysis  ................................ ................................ ................................ ...................... 39 
8.6. Pharmacodynamics  ................................ ................................ ................................ ......... 39 
8.7. Genetics  ................................ ................................ ................................ .......................... 39 
8.8. Biomarkers  ................................ ................................ ................................ ...................... 39 
8.9. Immunogenicity Assessments ................................ ................................ ......................... 40 
8.10.  Health Economics  ................................ ................................ ................................ ........... 40 
9. Statistical Considerations  ................................ ................................ ............................. 41 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....41 
9.2. Sample Size Determination  ................................ ................................ ............................ 41 
9.3. Populations for Analyses  ................................ ................................ ................................ 41 
9.4. Statistical Analyses  ................................ ................................ ................................ ......... 41 
9.4.1.  Primary Endpoint: Safety  ................................ ................................ ................................ 42 
9.4.2.  Secondary Endpoints: Pharmacodynamics and Pharmacokinetics  ................................ .42 
9.4.3.  Exploratory Endpoint: Efficacy  ................................ ................................ ...................... 43 
9.5. Interim Analyses  ................................ ................................ ................................ ............. 43 
9.6. Data Monitoring Committee  ................................ ................................ ........................... 43 
10. Supporting Documentation and Operational Considerations  ................................ ..44 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  7 10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 44 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 44 
10.1.2.  Financial Disclosure ................................ ................................ ................................ ........ 44 
10.1.3.  Informed Consent Process  ................................ ................................ .............................. 45 
10.1.4.  Data Protection ................................ ................................ ................................ ................ 45 
10.1.5.  Dissemination of Clinical Study Data ................................ ................................ ............. 46 
10.1.6.  Data Quality Assurance  ................................ ................................ ................................ ..46 
10.1.7.  Source Documents  ................................ ................................ ................................ .......... 47 
10.1.8.  Study and Site Start and Closure  ................................ ................................ .................... 47 
10.1.9.  Publication Policy  ................................ ................................ ................................ ........... 48 
10.1.10.  Investigator Information  ................................ ................................ ................................ .48 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 49 
10.3.  Appendix 3: Adverse Events: Definitions, and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  ................................ ......................... 50 
10.3.1.  Definition of AE  ................................ ................................ ................................ ............. 50 
10.3.2.  Definiti on of SAE  ................................ ................................ ................................ ........... 51 
10.3.3.  Recording and Follow -Up of AE and/or SAE  ................................ ................................ 52 
10.3.4.  Reporting of SAEs  ................................ ................................ ................................ .......... 54 
10.4.  Appendix 4: Liver Safety: Suggested Actions and Follow -up 
Assessments  ................................ ................................ ................................ .................... 55 
10.5.  Appendix 6: Blood Sampling Summary  ................................ ................................ ......... 57 
10.6.  Appendix 7: Abbreviations  ................................ ................................ ............................. 58 
11. References  ................................ ................................ ................................ ...................... 60 
 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  8 1. Protocol Summary  
1.1. Synopsis  
Protocol Title:  An Open -Label, Multi -Center, Single -Dose Study to Assess the Safety, 
Tolerability, Pharmacodynamics, and Pharmacokinetics of Nasal Glucagon in Pediatric Patients 
with Type 1 Diabetes  Aged 1  to <4 years  
Short Title:  A Single -Dose Study to Assess Nasal Glucagon in Pediatric Patie nts with Type 1 
Diabetes  aged 1  to <4 years  
Rationale : The primary aim of Study I8R -MC-IGBO (IGBO) is to assess the safety and 
tolerability of a 3  mg dose of NG (commercial drug product) in pediatric participants aged 1 to 
<4 years with T1D in an inpatient  clinical research facility . 
Objectives and Endpoint s  
Objectives  Endpoints  
Primary   
To assess the safety and tolerability of a single dose of 
NG 3 mg in children aged 1  to <4 years with T1D  Incidence of treatment -emergent adverse events.  
Secondary   
To assess the PD of a single dose of NG 3 mg in 
children aged 1  to <4 years with T1D  Change from baseline (predose BG) of maximum 
blood glucose.  Other blood  glucose parameters:  
 BGmax  
 AUC 
 TBGmax  
To assess the PK of a single dose of NG 3 mg in 
children aged 1 to <4 years  with T1D  Model -estimated population PK parameters  
 
Overall Design : Study IG BO is a Phase 1,  open -label, multi -center study with a primary 
objective of assessing safety and tolerability of a single 3 mg dose  of NG in pediatric participants 
aged 1 to <4 years with T1D.  
Participants will attend study visits, including screening, in the company of 1 or more parents or 
legal guardians, and in accordance with local healthcare facility practice.  
The study comprises a single cohort, wi th each participant receiving a single dose of 3 mg NG.  
Disclosure Statement : This is a single -arm, open -label  pediatric study. 
Number of Participants:  At least 9 participants with an approximate maximum of 20 may be 
enrolled  so that 6 evaluable participa nts complete the study.   
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  9 Intervention Groups  and Duration : 
Each participant is expected to participate in the study for up to approximately 7 weeks, from 
screening through follow -up. 
Data Monitoring Committee:  No 
1.2. Schema  
 
* Predosing -visit telephone call is not required if screening takes place on Day -1.
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  10 1.3. Schedule of Activities  (SoA)  
Procedure  Screening  
Visit  Predosing -visit 
preparation  
reminder 
(telephone)  Dosing 
Visit Follow -up 
(telephone)  Second  
Follow -up 
(telephone)  
Comments  
Day -35 to 
Day -1  Day -1 Day 1  Day 2  Day 9± 3 
Informed consent  X     Provided by [CONTACT_7078]/ legal guardian. Should be obtained 
before  any study -related procedures are performed.  
May be obtained during a separate informed consent 
visit to the site.  
Demographics  X     Full date of birth  (day, month, year), sex, and 
ethnicity will be collected, if consistent with  local 
regulations.  
Medical history  X      
Education on 
specifics of dosing 
visit  X X    Discussion between site staff and parent/ legal 
guardian on the target blood glucose range and 
information for dosing visit. See Section 5.1. 
Eligibility  X     See Section 5. 
Height  X      
Weight  X  X   On Day 1, body weight will be measured predose.  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  11 Procedure  Screening  
Visit  Predosing -visit 
preparation  
reminder 
(telephone)  Dosing 
Visit Follow -up 
(telephone)  Second  
Follow -up 
(telephone)  
Comments  
Day -35 to 
Day -1  Day -1 Day 1  Day 2  Day 9± 3 
Vital signs (body 
temperature, blood 
pressure, pulse rate)  X  X   See Section  8.2.2 . On Day 1, vital signs should be 
measured predose and 45 min postdose.  Time points 
may be added on Day 1 if warranted, at the discretion 
of the investigator.  
Clinical laboratory 
tests X     See Appendix 2 (Section 10.2) for details. Participants  
do not need to fast for laboratory samples.  Laboratory 
tests will be processed at a local labor atory.  
Age-appropriate 
physical examination  X      
Adverse event 
assessment  X  X X X AE assessment at telephone follow -up requires  
conversation with parent/ legal guardian about any 
AEs experienced by [CONTACT_40198]. 
Concomitant 
medication 
assessment  X  X X X On Day 1, concomitant medication assessment should 
be conducted  predose.  
Pre-admission 
contact [CONTACT_729992]/ legal guardian    X   Contact [CONTACT_7078]/ legal guardian  to check BG levels are 
suitable for study procedures. Before participant and 
parent/legal guardian leave home, within 
approximately 2 hours before dosing.  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  12 Procedure  Screening  
Visit  Predosing -visit 
preparation  
reminder 
(telephone)  Dosing 
Visit Follow -up 
(telephone)  Second  
Follow -up 
(telephone)  
Comments  
Day -35 to 
Day -1  Day -1 Day 1  Day 2  Day 9± [ADDRESS_997034] no food or 
beverage intake other than water within 3  hours 
before dosing . 
Verification  of 
hypoglycemia 
history since 
screening    Predose    See Section 5.2.1 . 
Allocation of 
participant 
enrollment number    X   Once eligibility  is confirmed  and participant is ready 
for dosing.  
Baseline glucose 
measurement    X   See Section  4.1.4 . 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  13 Procedure  Screening  
Visit  Predosing -visit 
preparation  
reminder 
(telephone)  Dosing 
Visit Follow -up 
(telephone)  Second  
Follow -up 
(telephone)  
Comments  
Day -35 to 
Day -1  Day -1 Day 1  Day 2  Day 9± [ADDRESS_997035] 
basal rate or 
administer a small 
bolus via insulin 
pump ; or for MDI,  
infuse a small 
correction bolus of 
insulin diluted in 
normal saline 
through IV  or by [CONTACT_729993]’s discretion.  See Section 4.1.4 . 
Nasal inspection  X  Predose , 
90 min   Visual nasal inspections. On Day 1, the predose 
inspection, administration of NG, and postdose 
inspection (90 min) should all be done by [CONTACT_113804].  
Return insulin pump 
basal rate to pre-
study settings     Postdose   For pump users only. If basal rate  was adjusted to 
achieve target blood glucose  on the study day , the 
basal rate must be returned to participant’s normal 
rate prior to discharge . 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  14 Procedure  Screening  
Visit  Predosing -visit 
preparation  
reminder 
(telephone)  Dosing 
Visit Follow -up 
(telephone)  Second  
Follow -up 
(telephone)  
Comments  
Day -35 to 
Day -1  Day -1 Day 1  Day 2  Day 9± 3 
NG administration    X   Nasal glucagon will be administered  only if a 
participant’s baseline glucose level is within target 
range. See Section  4.1.4 . 
Sample collection for 
measurement of 
plasma glucagon 
(pharmacokinetic s)   10, 30, 60  
min   Time points are relative to NG administration.  
Bedside glucose 
safety measurements    X   Measured using a point -of-care blood glucose testing 
device: either CGM, if applicable, via IV cannulation, 
or using an approved BG  meter. See Sectio n [IP_ADDRESS] . 
Blood glucose readings will be taken every [ADDRESS_997036] 30 min  after dosing , and then every 
20 min up to 90 min. Additional measurements may 
be taken  at investigator’s discretion . 
When a planned bedside safety sample coincides with 
a PD sample, the PD sample may be used for bedside 
safety assessment . 
Sample collection for 
measurement of 
plasma glucose 
(pharmacodynamic s)   P, 10, 30, 
60, 90 min   Measured  with study -approved rapid glucose analyzer 
(Section 8.6). Timings are relative to NG 
administratio n.  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  15 Procedure  Screening  
Visit  Predosing -visit 
preparation  
reminder 
(telephone)  Dosing 
Visit Follow -up 
(telephone)  Second  
Follow -up 
(telephone)  
Comments  
Day -35 to 
Day -1  Day -1 Day 1  Day 2  Day 9± 3 
Meal    X   Following completion of all study procedures, the 
participant will be provided a meal  including 
carbohydrates , and the investigator will ensure the 
participant’s plasma glucose is stable  prior to 
discharge .  
Discharge from site    X   Participants may be discharged after 4 hours postdose 
safety monitoring is complete. If required , a 
participant may remain in clinic  for further 
observation, at the discretion of the investigator.  
Abbreviations: AE = adverse event; BG = blood glucose; CGM  = continuous glucose monitoring; IV = int ravenous; MDI = multiple daily injection; NG = nasal 
glucagon; P = predose ; PD = pharmacodynamics; PI = principal investigator ; SC = subcutaneous . 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  16 2. Introduction  
2.1. Study Rationale  
The primary aim of Study I8R-MC-IGBO (IGBO) is to assess the safety and tolerability of a 
3 mg dose of NG (commercial drug product)  in pediatric participant s aged 1 to <4 years with 
T1D in an inpatient clinical research facility . 
2.2. Background  
NG (also known as Baqsimi; LY900018) is a drug -device combination product consisting of a 
single -use nasal dosing device that delivers glucagon powder  for absor ption through the nasal 
mucosa. NG provides the same single -chain, 29 -amino -acid polypeptide as human glucagon and 
the recombinant DNA -produced glucagon used in currently marketed glucagon emergency kits  
(Glucagon Emergency Kit [ Eli Lilly  and Company ] and GlucaGen ® HypoKit [Novo Nordisk 
A/S]) . It is approved for use as a treatment for severe hypoglycemia in adults and pediatric 
patients with diabetes mellitus aged ≥4  years . It has not been studied in children aged <4 years . 
The principal action of NG is to increase BG concentration through the action of glucagon in the 
liver.  
The formulation contains 3 mg of glucagon, as well as beta -cyclodextrin (a compendial excipi[INVESTIGATOR_729982]  a filler/ bulking agent/ absorption enhancer ), and dodecylphosphocholine (a novel 
excipi[INVESTIGATOR_729983]/surfactant) . 
The same drug -device combination product that is approved for use in patients aged 4 years  and 
older will be used in this study in pediatric participants aged 1  to <4 years . 
2.3. Benefit/Risk Assessment  
NG is administered by [CONTACT_729994] , 
which actuates the device to deliver the NG powder i nto the nasal mucosa.  The tip of the device 
is of similar size with similar drug product volume to other currently marketed devices approved 
and used for pediatric intranasal spray administration  in patients aged <4 years  including 
Nasa cort® (Children’s Nasacort USPI, 2015), Narcan® Nasal Spray (Narcan Nasal Spray PIL , 
2020) , Sterimar ™ (Sterimar Package Insert, 2019), and Ca lpol® Saline Nasal Spray (Calpol  PIL, 
2010). 
Due to the insertion of the device into the nostril, there is some risk of local nasal discomfort, 
irritation , and possibly trauma.  To minimize the se risks, NG will be administered by [CONTACT_729995] .  
NG has been approved as safe and effective  for the treatment of severe hypoglycemia in patients 
with diabetes aged ≥4 years . As part of the clinical development program i t was tested in the 
pediatric population aged  between 4 and <17 years in 1 clinical trial and 1 actual -use study . A 
description and outcomes of these studies are provided in Section [IP_ADDRESS] . The results of this 
current study will provide information that may contribute to ward the approval for the treatment 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  17 of severe hypoglycemia with NG in pediatric patients with diabetes aged 1 to <4 years , allowing 
an additional  glucagon formulation treatment option for this population . 
More detailed information about the known and expected benefits and risks and reasonably 
expected  AEs of NG may be found in the  IB and  Baqsimi Package Insert (20 19). 
2.3.1.  Risk Assessment  
Risks related to IGBO study procedures, and how they will be mitigated, are described in 
Section  [IP_ADDRESS] . A summary of glucagon safety is in Section  [IP_ADDRESS] . 
[IP_ADDRESS].  Risks and Safety Considerations i n Study IGBO  
Baseline glucose target level 
Prior to dosing, each participant’s baseline glucose level should be within a target range of 70  to 
140 mg/dL for NG to be administered. This range is based on premeal target glucose values 
recommended by  [CONTACT_729996]  (DiMeglio et al. 2018) of 70  to 130 mg/dL, with a +10 mg/dL 
allowance for the upper limit.  
Refer to the Study Operations Manual for detailed instructions.  
This study avoids the induction of hypoglycemia (defined as BG <70 mg/dL; Abraham et al. 
2018),  to ensure  there is no more than a minimal increase in medical risk for the pediatric 
population.  
The investigator may consider rescue medication to pre -empt or treat  clinically significant or  
severe hypoglycemia if indicated by [CONTACT_729997].  
If a participant’s baseline BG level  is 
 <70 mg/dL, the investigator will determine whether to proceed with dosing or to use 
rescue treatment (Section  8.3.6 ).  
 <54 mg/dL (clinically significant hypo glycemia  [Level 2 ]), site will halt study drug 
procedure and use rescue therapy  to raise BG  level . 
If rescue therapy is administered, the participant should remain at the site until stable based on 
investigator observation and clinical judgment. The visit may be rescheduled for a subsequent 
day at  the investigator ’s discretion , and according to the Manual of Operations.  
If the participan t does not return to the site for a subsequent visit in which required study 
procedures are completed, the participant must be discontinued from the study.  
Blood sampling  
The number and volume of blood samples for each participant  have been minimized to reduce 
the potential risks and lower the burden of study procedures for pediatric participants.  
Glucose safety monitoring  
Though hypoglycemia is not induced in this study, there is the potential for a participant to 
experience hypoglycemia. Participants’ BG level will be monitored at the bedside during and 
after NG administration, and the investigator may consider use of glucose or glucagon to 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  18 pre-empt or treat severe hypoglycemia . See Section [IP_ADDRESS]  for detail s on this bedside glucose 
safety monitoring, and Section 8.3.6 for detail of the rescue procedure.  
Needle pu nctures  
There is a small risk associated with needle punctures for blood sampling , which in some 
instances may cause bleeding, bruising, discomfort , infections , and/or pain.  Use of 
age-appropriate equipment will be used to minimize risks associated with these procedures. In 
addition, use of local anesthetics (e.g., Emla® cream) consistent with local prescribing 
information is permitted during the study visit to ease discomfort associated with venipuncture. 
To minimize venipuncture and adhere to blood volume restrictions, laboratory tests have been 
minimized.  
[IP_ADDRESS].  Historical Summary of Glucagon Safety  
Injectable  glucagon  
There has been extensive patient exposure to recombinant glucagon with injectable 
administration  for approximately [ADDRESS_997037] been reported in patients who received glucagon by [CONTACT_17838] . It is 
contraindicated in patients with known hypersensitivity to it , or in patients with known 
pheochro mocytoma  or insulinoma .  
Inclusion and e xclusio n criteria in this study were designed  to mitigate these risks.  
Nasal glucagon  
NG was approved in the US and Europe in 2019  for the emergency treatment of severe 
hypoglycemia in patients with diabetes aged 4 years and above .  
The NG development program demonstrated that NG is safe in both adult and pediatric patients 
aged ≥4 years.  The program included 10 studies in adults (healthy subjects and patients with 
diabetes) and [ADDRESS_997038] com monly reported AEs in the NG 
development program were  vomiting , headache, nausea , and “upper respi[INVESTIGATOR_729984] ” 
(rhinorrhea, nasal discomfort, nasal congestion, cough, and epi[INVESTIGATOR_3940] ), watery eyes, redness of 
eyes, sneezing, and itchy nose, throat , and eyes . 
The NG formulation in Study IGBO is the commercial drug product, which was also used in 
adult Studies I8R -MC-IGBI and I8R -MC-IGBJ . Study IGBI was  a multi -center, randomized, 
open -label, 2 -treatment, 2 -period, single -dose, crossover study in adult  patients with T1D that 
compared glucagon administered through  either the nasal route ( NG) or the intra -muscular route 
(GlucaGen) in the recovery from hypoglycemia induced by a controlled insulin infusion . Study 
IGBJ was a Phase 3, multi -center, randomized, open -label, active comparator, single -dose, 2 -
period, 2 -treatment, crossover study of NG (LY900018) compared to intramu scular glucagon for 
treatment of insulin -induced hypoglycemia in adult Japanese patients with diabetes mellitus . 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  19 Summary of NG safety in pediatric patients  
NG was assessed in pediatric patients in Studies I8R-MC-IGBB and I8R-MC-B001 ( B001). In 
total in these studies, 58 patients aged 4 to <[ADDRESS_997039] 1 dose of NG.  
Study IGBB  evaluated PK, PD, safety , and tolerability of NG 2 mg and 3 mg in pediatric 
patients aged 4 to <17 years with T1D.  In this study, 36 patients with T1D received NG 3 mg, 
23 received NG 2 mg, and 24 received weight -based intramuscular glucagon.   
The following table summarizes adverse  reactions  that occurred in pediatric patients in Study 
IGBB at an incidence of ≥2%, following NG 3 mg administration . 
Adverse Reaction  NG 3 mg  
n = 36  
% 
Vomiting  30.[ADDRESS_997040] Irritationa  16.7 
Abbreviations:  n = number of patients ; NG = nasal glucagon.  
a Upper respi[INVESTIGATOR_729984] : nasal discomfort, nasal congestion, sneezing . 
Source: Baqsimi Package Insert, 2019.  
Nasal and ocular symptoms were also solicited in Study IGBB through a patient questionnaire.  A 
list of these symptoms and their incidence rates is included  in the Baqsimi Package Insert (2019) . 
Study B00 1 is a real -world study that evaluated the effectiveness and ease -of-use of NG 3 mg in 
pediatric patients aged 4 to <[ADDRESS_997041] common AEs were nasal discomfort 
(92.9% ), watery eyes (85.7%), headache (71.4%) , runny nose ( 64.3%), nasal congestion 
(50.0%), sneezing (50%) , and redness of eyes (42. 9%), with approximately 60% of events 
resolving within 1 hour.   
Three patients who disco ntinued from Study B001 due to a clinical event reported severe nasal 
discomfort and 1 patient withdrew consent for reasons not related to a clinical event.  
2.3.2.  Benefit Assessment  
There is no anticipated therapeutic benefit for the  participants in Study IGBO.  
Study IGBO is expected to help meet an unmet need by [CONTACT_729998] a n 
additional  rescue therapy with alternate route of administration for the treatment of sever e 
hypoglycemia in children aged 1  to <4 years . 
2.3.3.  Overall Benefit: Risk Conclusion  
Considering  the measures taken to minimize risk to participants of this study, the potential risks 
identified in association with  NG are justified by  [CONTACT_729999] 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  20 that does not require dose adjustment and provides an alternate route of administration for the 
T1D pediatric population  aged between 1 and <4  years . 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  21 3. Objectives  and Endpoints  
Objectives  Endpoints  
Primary   
To assess the safety and tolerability of a single dose of 
NG 3 mg in children aged 1  to <4 years with T1D  Incidence of treatment -emergent adverse events  
Secondary   
To assess the PD of a single dose of NG 3 mg in 
children aged 1  to <4 years with T1D  Change from baseline (predose BG) of maximum 
blood glucose.  Other blood  glucose parameters:  
 BGmax  
 AUC 
 TBGmax  
To assess the PK of a single dose of NG 3 mg in 
children aged 1  to <4 years  with T1D  Model -estimated population PK parameters  
Exploratory   
To assess the efficacy of a single dose of NG 3 mg in 
children aged 1  to <4 years with T1D  The proportion of participants achieving treatment 
success defined as an increase of blood  glucose 
≥20 mg/dL (1.11 mmol/L)  from baseline  (predose BG) 
within 30 min postdose  
Abbreviations: AUC = area under the concentration -time curve; BGmax = maximum observed blood glucose; NG = 
nasal glucagon; PD = pharmacodynamics; PK = pharmacokinetics; T1D = type 1  diabetes; TBGmax = time of 
maximum observed blood glucose . 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  22 4. Study Design  
4.1. Overall  Design  
Study IG BO is a Phase 1,  open -label, multi -center study with a primary objective of assessing 
safety and tolerability of a single 3 mg dose  of NG in pediatric participants aged 1  to <4 years 
with T1D.  
Participants will attend study visits , including screening,  in the company of 1 or more parents or 
legal guardians, and in accordance with local healthcare facility practice . For simplicity , the term 
“parent/ legal guardian” will be used in the singular throughout this protocol.  
The study comprises a single cohort , with each participant rec eiving a single dose of [ADDRESS_997042] 9 participants with an approximate maximum of  20 may be enrolled  so that 6 evaluable 
participants complete the study.  See Section 9.4 for definitions of evaluable participants.  
For the purposes of this study, a participant completes the study after the conclusion of the 
second follow -up telephone call  on Day 9 ( ±3). 
Study g overnance considerations are described in detail in  Appendix 1, Section 10.1. 
Section 1.[ADDRESS_997043] as shown in the SoA.  
In addition to screening tests, the screening visit will include an information session for the  
participant’s parent/ legal guardian on the target BG range for dosing day, including  
 the target range for the participant’s BG on dosing day  
 how the parent/ legal guardian can help achieve this target BG level, including  
o the recommend ation  that participan ts have a natural overnight fast if possible, 
assuming morning dosing. At a minimum, participant s should have no food or 
beverage intake other than water within 3 hours before dosing  
o parent/legal guardian participat ion in  a predosing -visit telephone remind er on 
Day -1 (if required – see Section 4.1.2 ), and respon ding to contact [CONTACT_730000] a range appropriate 
for the scheduled visit.  
4.1.2.  Predosing-Visit Telephone Reminder  
On Day -1, site staff will telephone the participant’s parent/ legal guardian to give a remind er 
about the procedure for dosing day, including  
 the recommend ation  that participants have a natural overnight fast if possible, assuming 
morning dosing. At a minimu m, participant s should have no food or beverage intake 
other than water within 3 hours before dosing ,  
 the target BG level, and 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  23  that site staff will be in contact [CONTACT_730001]’s BG level is likely to be in the required range for dosing.  
Note  that this postscreening call may be omitted if the screening visit was on Day -1.  
4.1.3.  Day 1: Call/ Text on Morning of Dosing   
On Day 1, before each participant is expected to leave their home to travel to the  site, site staff 
will call or send a text message to the parent/ legal guardian soliciting  
 a measurement of the participant’s BG level  and  
 the participant’s physical status  to participate  and attend the visit. 
The BG  measurement  can be taken  either via the participant ’s own CGM device or using an 
appropriate glucometer , and will be used to determine whether the baseline BG level is likely to 
be within the target  range  at the time of dosing at the site .  
Based on this information , the PI [INVESTIGATOR_113961] d ecide to proceed or reschedule the visit (Section 4.1.8 ).  
4.1.4.  Day 1: Predose  
For the dosing visit (Day 1), it is recommend ed that participants have a nat ural overnight fast if 
possible, assuming morning dosing. At a minimum, participant s should have no food or beverage 
intake other than water within 3 hours before dosing . 
At the study site, BG will be measured  to determine if the participant’s baseline BG level is 
within the target range of 70  to 140 mg/dL (Section [IP_ADDRESS] ), and confirm ability to proceed with 
dosing and other study procedu res.  
If BG is  
 below the target range, rescue treatment may be considered (Section 8.3.6 ).  
 above the target range, the investigator may choose to  
o in the case of pump users, increase the basal insulin rate  of the participant’s 
insulin pump , or initiate a small bolus dose , to achieve target BG  
o in the case of MDI users : administer a small correction bolus via SC injection 
of insulin or IV infu sion of insulin diluted in normal saline  to achieve target 
BG  
o wait and allow BG to decrease  to target level  if BG is already decreasing , or 
o reschedule the visit (Section 4.1.8 ). 
If a bolus dose of insulin is administered  via the pump , or insulin is administered  to patients on 
MDI, the dose level will be based on PI [INVESTIGATOR_9106] .  
The basal rate or insulin infusion may be adjusted at the discretion of investigator  during study 
procedures  as necessary to protect participant  safety . 
For pump users only, i f the investigator adjusts the pump basal rate setting , it may be returned to 
pre-study settings after [ADDRESS_997044] be returned to participant’s usual 
setting prior to discharge . Additionally, site staff must  confirm the basal settings with the 
parent/legal guardian before the participant is  discharged.  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  24 4.1.5.  Day 1: Dosing  
NG will be administered within 5 minutes of predose BG measurement by [CONTACT_730002] a recumbent or semi -recumbent position . 
The tip of the device is gently inserted in the nostril.  At that point, the  plunger  of the device is 
pushed firmly  until the green line is no longer showing , which indicates  that the dose is 
complete. The drug is absorbed from the nasal  cavity; thus the participant  does not need to inhale 
after dosing .  
If a participant  sneezes immediately after administration,  site staff should  document  this in the 
eCRF . All postdose assessments, including PK and PD sampling, would still occur in this case.  
[IP_ADDRESS].  Suspected Administration Fa ilure  
If site staff are not able to successfully dose  – e.g., due to  device malfunction, or the child 
forcefully moving their head away – there will be a 30-minute period during which safety and 
PD blood sampl ing will proceed . At 30 min utes, if PD and safety sampling show that the 
participant ’s BG levels  are in the target range (Section [IP_ADDRESS] ), a second dose may proceed , at 
the discretion of the PI [INVESTIGATOR_142332]’s parent/legal guardian .  
4.1.6.  Day 1: Po stdose  
After dosing, bedside glucose safety measurements will be taken with either the participant’s 
own CGM device , or with an approved point -of-care glucometer using capi[INVESTIGATOR_117812], 
as described in Section  [IP_ADDRESS] . 
Venous b lood samples will be taken for PK measurement s. 
Following study procedures, participant s will be given a meal including carbohydrate s, and 
discharged.  Discharge may be delayed  if the investigator determines that  further observation is 
needed . 
4.1.7.  Follow -up 
Site staff will conduct 2 follow -up telephone calls with the parent /legal  guardian to discuss any 
potential side effects or AEs: 
 on Day 2  
 on Day 9 (± 3 days). 
4.1.8.  Rescheduling Visits 
A participant’s dosing visit may be rescheduled, up to a maximum of 2 times, if  
 based on the Day 1 communication  prior to the participant traveling to site  (Section 4.1), 
the PI [INVESTIGATOR_530700] s that the participant’s BG level is unlikely to be within the target range 
in time for dosing , or 
 a participant’s baseline BG level , as measured on site prior to dosing,  is outside the target 
range and may not be achi eved within a time  frame suitable for completion of all required 
visit procedures (Section 4.1.4 ), or  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  25  a participant has an acute illness such as influenza, ear or respi[INVESTIGATOR_4416], or other 
illness  that in the opi[INVESTIGATOR_729985] . 
Note that if the device malfunctions and no dose is delivered, rescheduling is not required  and 
dosing may proceed with another device . See Section [IP_ADDRESS] . 
The dosing visit should be within 35 days of the screening visit . If this is not possible, additional 
time may be allowed between screening and Day 1 with documented approval from the sponsor.   
The dosing day will always be designated as Day 1 and subsequent study days number ed 
accordingly.  
In the event of rescheduled dosing visits, site staff may repeat as needed the postscreening 
communication  prior to the participant traveling to site . 
4.2. Scientific Rationale for Study Design  
NG 3 mg has demonstrated similar safety and PD responses across all completed adult and 
pediatric studies (age range 4  to <17 years ) in which injectable glucagon was used as an active 
comparator . Based on these data, Study IGBO  was designed without an active comparator, to  
eliminate unnecessary procedures and minimizes distress and discomfort for study participant s.  
4.3. Justification for Dose  
NG is approved for use in patients with diabetes aged 4 years  and above , at a dose level of 3 mg.  
A single dose of 3 mg NG was supported by [CONTACT_395494], tolerability, efficacy , and PK data 
generated during the NG development program.  
For pediatric patients with diabetes, the selection of a 3 mg dose was based on results from Study 
IGBB.  In that study  
 NG 3 mg was administered to all age groups (4 to <8, 8 to <12, and 12 to  <17 years).  In 
each group, NG 3 mg rapi[INVESTIGATOR_703080] a maximal BG increase,  similar to that of  
injectable glucagon  doses (0.5 or 1 mg  depending on the patient’s weig ht); 
 NG 2 mg and 3 mg were administered to the 2 younger age groups (4 to <8  and 8 to <12 
years). N G 3 mg produced a slightly higher glucose response  than NG 2 mg ; 
 NG 3 mg in pediatric patients showed similar tolerability and safety to NG 2 mg, and to 
weight -based  injectable glucagon  doses . 
Although 3 mg NG in 1- to <4-year-old participants is expected to result in higher systemic 
glucagon concentrations than those observed with 3  mg NG in older  pediatric patients , this 
transient high systemic exposure is expected to be safe . This expectation is based on published 
data with intravenous -administered glucagon  in adults (Graf et al. 1999), which showed 
exposures that were multiples higher than the projected maximum exposure following NG 
administration in pediatric patients aged 1  to <[ADDRESS_997045] . 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  26 4.4. End of Study  Definition  
The end of the study  is the date of the second follow -up telephone call shown in the SoA 
(Section 1.3) for the last  participant . 
 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  27 5. Study Population  
Eligibility of participants  for the study will be based on the results of screening medical history, 
physical examination, vital signs, and clinic al laboratory tests.  
The nature of any conditions present at the time of the physical examination and any preexisting 
conditions will be documented.  
Screening may occur up to 35 days prior to enrollment . At the investigator’s discretion, with 
documented approval from the sponsor, participants  who have  not attended a dosing visit  within 
35 days of screening may be subjected to an additional medical assessment and/or clinical 
measurements to reconfirm their eligibility.  Laboratory tests previously collected for the 
screening visit may be used to reconfirm eligibility.  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1. Inclusi on Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply  at 
screening : 
Age 
1. Are aged 1 to <[ADDRESS_997046] 6 months  as previously 
demonstrated by [CONTACT_730003] (glutamic acid 
decarboxylases; insulin -associated  tyrosine phosphatase antibody; insulin autoantibody; 
islet cell antibody) as per  medical records, or dia gnosis by [CONTACT_598007]  (pediatric 
or adult), or a physician with expertise in treating pediatric patients with T1D 
3. have been receiving insulin therapy via MDI , or continuous subcutaneous insulin infusion  
using a  pump , and have been stable on the therapy  and route of administration  for at least 
[ADDRESS_997047] a hemoglobin A1c level of ≤9.5% at screening  
5. have venous access sufficient to allow for blood sampling as per the protocol  
6. are in good general health with no conditions that could influence the outcome of the 
trial, and in the judgment of the investigator are a good candidate for the study based on 
review of available medical history, physical examination , and clinical laboratory 
evaluations with no prior history of choanal atresia , nasal/pharyngeal blockage , or 
anomaly.  
Availability and informed  consent  
7. participant and their parent/legal guardian a re reliable and willing to be available for the  
duration of the study, and to follow study procedures  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  28 8. the participant’s parent/legal guardian can provide  written informed consent  on behalf of 
the participant . 
5.2. Exclusion Criteria   
Participants are excluded from the study if any of the following criteria apply:  
Medical conditio ns 
9. have presence or history of hypersensitivity to glucagon or any related products; or 
severe hypersensitivity reactions, such as angioedema, to any medication  
10. have presence or history of any of the disorders in the following list, that in the opi[INVESTIGATOR_13046], could significantly alter the absorption, metabolism, or elimination of 
drugs; constitute a risk when  taking the investigational product; or interfere with the 
interpretation of data:  
 cardiovascular , 
 respi[INVESTIGATOR_696] , 
 hepatic , 
 renal , 
 gastrointestinal , 
 endocrine (other than T1D) , 
 hematological, or  
 neurological disorders  
 suspected low glycogen stores due to chronic low carbohydrate intake  or inadequate 
diet. 
11. have a history of pheochromocytoma (i.e. , adrenal gland tumor) or insulinoma  
12. have a history of epi[INVESTIGATOR_93376]  
13. have 1 or more congenital anomalies to the anatomy of the nose, or require changes to the 
anatomy of the nose (e.g. , are eligible for nasal pharyngeal surgery ) 
14. have history or presence of laryngopharyngeal reflux  
15. have an abnormal blood pressure and/or pulse rate as determined by [CONTACT_093]  
16. in the [ADDRESS_997048] had an epi[INVESTIGATOR_66677], defined 
as a hypoglycemia event with severe cognitive impairment (including coma and 
convulsions) requiring assistance by [CONTACT_730004], 
glucagon, or take other corrective actions (Abraham et al. 2018)  
17. have clinically significant multiple or severe drug allergies, or into lerance to topi[INVESTIGATOR_030], or severe posttreatment hypersensitivity reactions (including, but not 
limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic 
epi[INVESTIGATOR_194], or exfoliative dermatitis)  
18. have a history  of human immunodeficiency virus infection and/or positive human 
immunodeficiency virus  antibodies  
19. have a history of hepatitis C and/or positive hepatitis C antibody  
20. have  a history of hepatitis B and/or positive hepatitis B surface antigen  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  29 Prior/ concomitant therapy  
21. are regularly administered a systemic beta -blocker, indomethacin, warfarin , or drugs 
classified as anticholinergics, or corticosteroids; or regular use of other medications, 
pending discussion between the investigator and the study clinical pharmacologist  or 
CRP  
22. are using closed -loop insulin therapy, UNLESS such a device  is set to ‘open 
loop/manual’ mode  and the automated low glucose suspend or predictive low glucose 
suspend are disabled on the day of the dosing visit  until all PK and PD samp les have been 
collected . 
Prior/ concurrent clinical study experience  
23. are currently enrolled in a clinical study involving an investigational product or any other 
type of medical research judged not to be scientifically or medically compatible with this 
study 
24. have participated, within the past [ADDRESS_997049] has a long half -life, 5 half -lives or 
30 days (whichever is longer) should have passed . 
Other exclusions  
25. are related to either a Lilly employee; an employee of a third -party organization involved 
in this study; or investigative site staff directly affiliated with this study  
26. in the opi[INVESTIGATOR_26335], the participant or their parent/ legal guard ian 
is unsuitable for inclusion in the study.  
5.2.1.  Additional Exclusion Criteria Prior to Dosing Visit (Day 1)  
27. have had an epi[INVESTIGATOR_66677] , or have had glucagon administered, during  
the period between the screening visit and the dosing visit . An epi[INVESTIGATOR_729986] a hypoglycemia event with severe cognitive impairment 
(including coma and convulsions) requiring assistance by [CONTACT_730005], glucagon, or take other corrective actions  (Abr aham et al. 
2018) . 
5.3. Lifestyle Considerations  
5.3.1.  Meals and Dietary Restrictions  
It is recommended that participants have a natural overnight fast if possible , assuming morning 
dosing . 
At a min imum, participant s should have no food or beverage intake other than water within 
3 hours before dosing.  
 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  30 5.4. Screen Failures  
Screen failures are defined as participant s who se parent/legal guardian  consent ed for them  to 
participate in the clinical study  but who are not subseque ntly enrolled in the study.  A minimal set 
of screen failure information is required to ensure transparent reporting of screen  failure 
participant s to meet the Consolidated Standards of Reporting Trials  publishing requirements and 
to respond to queries from  regulatory authorities. Minimal information includes demography, 
screen failure details, eligibility criteria, and any SAE . 
Individuals who do not meet the criteria for participation in this study (screen failure)  or were  
required to unexpectedly discontinue from the study during screening or lead -in period (e.g., due  
to enrollment pause related to the coronavirus disease -19 or other public health emergency)  may 
be re -screened once, at the investigator  and sponsor ’s discretion. In the case of rescr eening, the 
participant’s previous screening blood chemistry results may be used if they were taken within 
the previous [ADDRESS_997050] be signed . 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  31 6. Study Intervention  
Study intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo , or medical device (s) intended to be administered to /used by  a study participant 
according to the study protocol.  
6.1. Study Intervention Administered  
Intervention Name  [CONTACT_730018] -Device  
Dose Formulation  Powder  
Dosage Level(s)  [ADDRESS_997051] /noninvestigational 
medicinal product  investigational medicinal product  
Sourcing  Provided centrally by [CONTACT_730006](s) or Alias(es)  Baqsimi ; LY900018  
6.1.1.  Administration Details  
See Section 4.1.5  for an overview of NG administration. Further detail is in  the NG Instructions 
for Use . 
6.2. Preparation/Handling/Storage/Accountability  
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention s received and any discrepancies are reported 
and resolved before use of the study intervention.  
Only participants enrolled in the study may receive study intervention and only authorized site 
staff may supply or administer study intervention. All study intervention s must be stored in a 
secure, environmentally controlled, and m onitored (manual or automated) area in accordance 
with the labeled storage conditions with access limited to the investigator and authorized site 
staff.  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  32 The investigator, institution, or the head of the medical institution (where applicable) is 
responsible  for study intervention accountability, reconciliation, and record maintenance (i .e., 
receipt, reconciliation, and final disposition records).  
Unused study materials  will remain locked and securely stored  until returned to the sponsor or  
destroyed, accordi ng to written instruction from the sponsor . Further guidance and information 
for the final disposition of unused study materials  are provided  in the Pharmacy Manual.  
6.3. Measures to Minimize Bias: Randomization and Blinding  
Not applicable as this is a single -arm study.  
6.4. Study Intervention Compliance  
Participants will receive study intervention directly from the investigator or designee, under 
medical supervision. The date and time of each dose administered in the clinic will be recorded 
in the source documents a nd in the eCRF. The dose of study intervention and study participant 
identification will be confirmed at the time of dosing by a member of the study site staff other 
than the person administering the study intervention.  
6.5. Concomitant Therapy  
Participants  on stable concomitant medications at the time of study entry, as defined in 
Section  5.2, Exclusion Criterion 21 , should continue their regular, unchanged dose throughout 
the study .  
For participants using CGM, c oncomitant medications or supplements in doses that may interfere 
with CGM measurements according to the label should not be taken within 48 hours prior to  the 
dosing visit.  
In general, new concomitant medication s should be avoided; however, acetaminophen or similar 
medication may be administered at the discretion of the in vestigator postdosing for treatment of 
pain or discomfort . If the need for other  concomitant medication arises, inclusion or continuation 
of the participant  may be at the discretion of the investigator in consultation with a Lilly clinical 
pharmacologist.  Any medication used during the course of the study must be documented  in the 
eCRF . All changes in concomitant medications made during the study should be recorded  in the 
eCRF . 
6.6. Dose Modification  
Dose modification is not allowed in this study.  
Due to the des ign of the NG drug-device, a full [ADDRESS_997052] been  
completed . 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  33 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
7.1. Discontinuation of Study Intervention  
Not applicable as this is a single -dose study.  
7.2. Participant Discontinuation/ Withdrawal from the Study  
A participant  may withdraw from the study  
 at any time at his/her own request  
 at the request of his/her designee ( e.g., parent /legal guardian)  
 at the discretio n of the investigator for safety, behavioral, compliance, or 
administrative reasons  
 due to  enrollment in any other clinical study involving an investigational 
product , or enrollment in any other type of medical research judged not to be 
scientifically or medically compatible with this study  
 if their  baseline  BG is below 54 mg/dL as described in Section [IP_ADDRESS] . 
If consent  is withdrawn for disclos ure of future information, the s ponsor may retain and continue 
to use any data collected before such a withdrawal of consent . If a participant  is withdraw n from 
the study, their parent/ legal guardian may request destruction of any samples taken and not 
tested , and the investigator must document this in the site study records . 
7.2.1.  Discontinua tion of Inadvertently Enrolled Participants  
If the sponsor or investigator identifies a participant who did not meet enrollment criteria and 
was inadvertently enrolled, then safety follow -up should be performed as outlined in Section 1.3 
(Schedule of Activities), Section 8.2 (Safety Assessments) , and Section 8.3 (Adverse Events and 
Serious Adverse Events) of the protocol.  Such participants would be classified as discontinued.  
7.3. Lost to Follow -up 
A participant will be considered lost to follow -up if the participant’s parent/ legal guardian is 
unable to be contact[CONTACT_730007] -up telephone calls . Site staff are expected to 
make diligent attempts to contact [CONTACT_4317] ’ parent /legal guardian for follow -up.  
Discontinuation of specific sites or of the study as a whol e is handled as part of Appendix 1  
(Section 10.1). 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  [ADDRESS_997053].  
Investigators or relevant clinical staff will provide age -appropriate explanations to all children 
prior to any assessment or procedure as appropriate.  Investigators should assess and monitor 
physical pain and distress at each visit. Clinical s taff trained or experienced in pediatric 
phlebotomy should perform blood draws at the clinic.  
Use of local anesthetics (e.g., E mla cream) and other techniques to p romote viable ease in blood 
sampling  consistent with local prescribing information are permitted during the study visit to 
ease discomfort associated with venipuncture.  Owing to blood volume restrictions, laboratory 
tests have been minimized.  
All screening  evaluations must be completed and reviewed to confirm that  potential participant s 
meet all eligibility criteria.  The investigator will maintain a screening log to record details of all 
participant s screened and to confirm eligibility or record reasons for  screening failure, as 
applicable.  
8.1. Efficacy Assessments  
Efficacy of NG may be assessed as an exploratory objective, based on PD parameters. See 
Section 9.4.3 . 
8.2. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA.  
8.2.1.  Physical Examinations  
An age -appropriate physical examination will be conducted.  
8.2.2.  Vital Signs  
For each  participant , vital sign measurements will be conducted according to the S oA 
(Section  1.3). 
Blood pressure and pulse rate  should  be measured with the participant sitting and relaxed  when 
possible . Blood pressure measurements should be determined using a correctly sized  cuff. 
Additional vital signs may be measured for participant safety at the dosing visit , at the discretion 
of the investigator.  
8.2.3.  Clinical Safety Laboratory Assessments  
For each participant , laboratory tests detailed in  Section 10.2 should be conducted according to 
the S oA (Section 1.3). 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  [ADDRESS_997054] or CRP/scientist will monitor safety data throughout the course 
of the study . 
Lilly will review SAEs within time frames mandated by [CONTACT_10984].  The Lilly clinical 
pharmacologist or CRP  will periodically review vital signs, safety , and AEs.  
[IP_ADDRESS].  Bedside Glucose Safety Monitoring  
During and after dosing, BG levels will be measured at the bedside for safety monitoring using 
an approved point -of-care glucometer. This will be 1 of 2 types, as follows:  
 If the participant has been using an approved CGM in accordance with the device label 
for at least 1 month prior to the dosing visit, this CGM may be used for safety 
monitoring . 
 If the participant has not been using an approved CGM, plasma BG levels for safety will 
be measured using a study -approved point -of-care glucometer . 
In both cases, refer to the Study Operations Manual for details.  
Timings of BG measurements are shown in the SoA (Section 1.3). 
8.2.5.  Monitoring for Hypoglycemia  
Severe hypoglycemia will be described using the following ISPAD defin ition (Jones 2018 ): 
Severe hypoglycemia in children:  because children have limited ability  to detect and/or 
self-treat hypoglycemia,  severe  hypoglycemia in children is  an event in which children  have 
severe cognitive impairment , and require external  assist ance, are semiconscious or  unconscious, 
or in coma  with or without  convulsions,  and require s another person to actively administ er 
carbohydrate s, glucagon , or take other corrective action.  
The determination of a hypoglycemic event as an epi[INVESTIGATOR_66677], as defined 
above, will be made by [CONTACT_730008] -induced cognitive dysfunction  and is not predicated on the report of a participant  
simply having received assistance.  
All epi[INVESTIGATOR_729987].  
Use of intravenous  glucagon to preempt or treat severe hypoglycemia is described in  
Section  8.3.6 . 
8.2.6.  Nasal Inspections  
A visual nasal inspection will be conducted as specified in the S oA (Section 1.3), and more 
frequently if deemed necessary by [CONTACT_093]. The same investigator that conducts the 
predose inspection should perform the postdose inspection for consistency. Refer to the Study 
Operations Manual  for further details on this procedure . 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  36 8.2.7.  Hepatic Safety  Monitoring  
If clinically applicable, the investigator may obtain additional laboratory tests during the study to 
confirm any hepatic abnormalities that may occur.  Specific tests and follow -up procedures are 
provided in  Section 10.4 (Appendix 4).  
8.3. Adverse Events and Serious Adverse Events  
AEs will be reported by [CONTACT_730009], or the participant ’s parent/ legal guardian . 
The investigator and any qualified des ignees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study intervention , study device , or device 
constituent , or study procedures, or that caused the participant to discontinue the study  (see 
Section 7). 
A non -SAE  that can be attributed or related to study device or device constituent, where the 
device complaint/deficiency/problem was anticipated , is also referred to as an adverse device 
effect. 
An SAE attributable or related to an anticipated  study device or device constituent 
complaint/deficiency/problem is also referred to as a serious adverse device effect.  
An SAE attributable or related to an unknown or unanticipated device or device co nstituent 
complaint/deficiency/problem is also referred to as an unanticipated adverse device effect; or 
unanticipated serious adverse device effect in certain countries.  
A “reasonable possibility” means that there is a cause and effect relationship between the 
investigational device  product, i.e., study device or device constituent, and/or study procedure 
and the SAE.  
Immediate safety concerns should be discussed with the sponsor immediately upon occurrence or 
awareness to determine if the participant should continue or discontinue study intervention.  
8.3.1.  Time Period and Frequency for Collecting AE and SAE Information  
All AE s will be collected from the signing of the ICF until the completion of the second 
follow -up phone call . 
AEs that begin before the start of study intervention but after signing of the ICF will be  recorded 
on the Adverse Event eCRF.  
Although all AEs after signing the ICF are recorded by [CONTACT_29558]/ele ctronic data entry, 
SAE reporting to the sponsor begins after the participant’s  parent/ legal guardian  has signed the 
ICF and the participant has received study drug.  However, if an SAE occurs after signing the 
ICF, but prior to receiving  NG, it needs to be  reported ONLY if it is considered reasonably 
possibly related to study procedures.  
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated in Appendix 3. The investi gator will 
submit any updated SAE data to the sponsor within 24  hours of it being available.  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  37 Investigators are not obligated to actively seek AE s or SAE s after conclusion of the study 
participation . However, if the investigator learns of any SAE, including  a death, at any time after 
a participant has been discharged from the study, and he/she considers the event to be reasonably 
related to the study intervention or study participation, the investigator must promptly notify the 
sponsor . 
8.3.2.  Method of Detecting A Es and SAEs  
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Section  10.3 (Appendix  3). 
Care will be taken not to introduce bias wh ile detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant , participant’s parent /legal  guardian, and 
investigator assessment  are the preferred method to inquire about AE  occurrences . 
8.3.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow up with each 
participant ’s parent/legal guardian  at subsequent visits/contacts. A ll SAEs  will be followed up 
until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow -
up (as defined in Sectio n 7.3). Further information on follow -up procedures is provided  in 
Section  10.3 (Appendix 3).  
8.3.4.  Regulatory Reporting Requirements for SAEs  
Prompt notification by [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities toward the safety of participants and the safety of a study 
intervention under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulato ry authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
sponsor will comply with country -specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRBs/IEC s, and  investigators.  
An investigator who receives an investigator safety report describing a n SAE or other specific 
safety information ( e.g., summary or listing of SAEs) from the sponsor will review and then file 
it and will notify the IRB/IEC, if appropriate a ccording to local requirements.  
8.3.5.  Pregnancy  
Not applicable  for this study . 
8.3.6.  Rescue Treatment  
Rescue treatment may be considered to preempt or treat clinically significant or severe 
hypoglycemia based on BG measures taken at baseline (Section [IP_ADDRESS] ), or as part of bedside 
glucose safety monitoring during and after dosing (Section [IP_ADDRESS] ). 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  38 [IP_ADDRESS].  Criteria for Considering Rescue Treatment  
In general, the investigator may decide to start a glucose infusion if a participant’s BG level  is 
declining rapi[INVESTIGATOR_375],  or their symptoms become consi stent with progression to clinically significant 
or severe  hypoglycemia . 
In addition, specific BG thresholds for considering rescue treatment at baseline and during 
bedside glucose safety monitoring are as follows:  
Baseline  criteria for rescue  
If a participant’s baseline BG level  is 
 <70 mg/dL, the investigator will determine whether to proceed with dosing or to use 
rescue treatment.  
 <54 mg/dL (clinically significant hypo glycemia  [Level 2 ]), site w ill halt study drug 
procedure and use rescue therapy  to raise BG  level . Such participants ’ visits  may be 
rescheduled for a subsequent visit . 
[IP_ADDRESS].  Rescue Procedure  
Oral or intravenous  glucose or glucagon may be given as appropriate to the clinical situation.  If 
NG was administered, a ny remaining blood samples will be collected , if possible, according to 
the SoA.  
Further detail s will be provided to the site in the Study Operations Manual.  
8.3.7.  Product Complaints  
A product complaint is any written, electronic, or oral communication that alleges a deficiency  
related to the  identity, quality, durability, reliability, safety, effectiveness, or performance of a 
Lilly product after it is released to the study . When the ability to use the product safely is 
impacted, the following are also product complaints:  
a. Deficiencies in lab eling information, and  
b. Use errors for device or combination products due to ergonomic design elements of the 
product.  
The s ponsor collects product  complaints  on investigational products, medical devices, and drug 
delivery systems used in clinical studies t o ensure the safety of study participants, monitor 
quality, and to facilitate process and product improvements.   
Complaints  are also collected on comparators and other materials supplied, as required and 
instructed for the study.   
Participants ’ parent/lega l guardian  will be  instructed to contact [CONTACT_730010]  a complaint or problem with the investigational product , medical device , or 
delivery system, so that the situation can be assessed.  
Product  complaints  will be reported by [CONTACT_143234] -specific Product Complaint Form.   
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  [ADDRESS_997055] led to an SAE had 
precautions not been taken.  
8.4. Treatment of Overdose  
For the purposes of this study, an overdose of NG is considered any dose higher than the planned 
3 mg dose.  
In case of suspected overdosing, serum potassium levels may decrease and should be  monitored 
and corrected if needed. If the participant  develops a marked  increase in blood pressure, blood  
pressure medication appropriate to the child’s age may be administered, e.g. , phentolamine 
mesylate for ch ildren aged 3+ years (OraVerse USPI, 2018 ; Baqsimi USPI, 2019 ).  
Refer to the Product Label for additional details.  
8.5. Pharmacokinetics  
At the times specified in the  SoA, venous blood  samples of approximately 2 mL each will be 
collected to determine the  plasma  concentrations of glucagon . 
Instructions for the collection and handling of blood samples will  be provided by [CONTACT_456] . 
The actual date and time (24 -hour clock time) of each sampling will be recorded.  Sites may use 
topi[INVESTIGATOR_729988].  
8.5.1.  Bioanalysis  
Samples will be analyzed at a laboratory approved by [CONTACT_17077] a facility 
designated by [CONTACT_456] . 
Concentrations of  glucagon will be assayed using a validated liquid chromatography  with 
tandem  mass spectrometry  method . 
Bioanalytical samples collected to measure inves tigational product concentrations will be 
retained for a maximum of [ADDRESS_997056] participant  visit for the study.  
8.6. Pharmacodynamics  
At the times specified in the S oA, blood samples will be collected for use in a study -approved 
rapid glucose analyzer (YSI or equivalent)  to determine the plasma concentrations of glucose.   
Instructions for the collection and handling of blood samples will be provided by [CONTACT_456].  
The actual date and time (24 -hour clock time) of each sampling will be recorded.  
8.7. Genetics  
Genetics will not be evaluated in this study.  
8.8. Biomarkers  
Biomarkers will not be evaluated in this study.  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  40 8.9. Immunogenicity Assessments  
Not applicable.  
8.10. Health Economic s 
Not applicable.  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  [ADDRESS_997057] 9 participants with an approximate maximum of 20 may be enrolled so that 6 evaluable 
participants complete the study.  
The sample size is customary for Phase 1 studies evaluating safety, tolerability, PD, and PK, and 
is not powered on the basis of statistical hypothesis testing.  
The sample size assumes a 33% dropout rate.  
Participants  who are enrolled but not administered treatment  may be replaced  to ensure that 
enough participants  may complete the study . 
9.3. Populations for A nalyses  
A detailed description of  participant  disposition will be provided . 
The participants’  baseline characteristics and demographics will be obtained at entry and will be 
summarized  for all enrolled  participant s who proceed to the dosing visit . 
9.4. Statistical Analyses  
Statistical analysis of this study will be the responsibility of Lilly or its designee.  
Any change to the data analysis methods described in the pro tocol will require an amendment 
ONLY if it changes a principal feature of the protocol.  Any other change to the data analysis  
methods described in the protocol, and the justification for making the change, will be described  
in the SAP and/or in the clinical study report.  
All data will be entered, verified, and archived at a CRO  external to L illy and/or at Lilly. Data 
listings, summaries, and analyses will be performed by a  CRO and/or by [CONTACT_730011].  
Unless otherwise specified, efficacy analyses will be conducted  on all enrolled participant s who 
receive  the study drug and have an evaluable efficacy outcome  (based on PD parameters , see 
Section  9.4.3 ). 
PK and PD analyses will be conducted  on data from all enrolled participant s who receive the 
study drug  and have evaluable PK  or PD data . See Section 9.4.2  for definitions of evaluable PD 
and PK data.  
Safety analyses (Section 9.4.1 ) will be c onducted for all enrolled  participant s who receive at least 
1 dose of the study drug , whether or not they complete all protocol requirements.  
Additional exploratory analyses of the data will be conducted as deemed appropriate.  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  42 9.4.1.  Primary Endpoint : Safety  
[IP_ADDRESS].  Clinical Evaluation of Safety  
All investigational product  and protocol procedure AEs will be listed, and if the frequency of 
events allows, safety data will be summarized using descriptive methodology.  
The incidence of symptoms  will be presented by [CONTACT_11370] y and by [CONTACT_730012].  Symptoms reported to occur prior to enrollment  will be 
distinguished from those reported as new or increased in severity during the study.  Each 
symptom will be classified b y the most suitable term from the Medical Dictionary  for R egulatory  
Activities . 
The number of investigational product -related SAEs will be reported.  
Nasal/respi[INVESTIGATOR_729989]. The 
details will  be provided in the SAP . 
[IP_ADDRESS].  Statistical Evaluation of Safety  
Safety parameters that will be assessed include safety lab oratory  parameters  and vital signs. The 
parameters will be listed  or summarized using standard descriptive statistics. Additional analysis 
will be performed if warranted upon review of the data.  Details will be provided in the SAP . 
9.4.2.  Secondary Endpoint s: Pharmacodynamics and Pharmacokinetics  
[IP_ADDRESS].  Pharmacodynamics  
[IP_ADDRESS].1.  Pharmacodynamic  Parameter Estimation  
Due to limited number of PG measurements ( 5 time points), a limited number of PD parameters 
will be estimated. The primary PD parameter is change from baseline of BG max. In addition, 
other PG parameters , BGmax, AUC, and TBGmax  may also be estimated.  Actual sampling times 
will be used for all calculations . 
Baseline PG concentrations will be calculated from samples obtained immediately prior to 
glucagon dosing (e.g., predose).  
Other PD parameters of PG may be calculated if required.  Individual concentrations and PD  
parameters of  PG will be summarized using  descriptive statistics . 
[IP_ADDRESS].2.  Pharmacodynamic Statistical Summary   
The PD parameters (such as change from baseline of BG max, BGmax , AUC parameters , and 
TBGmax) will be summarized  using standard descriptive statistics .  
Evaluable PD data are defined as having baseline and at least 1 postbaseline measure.  For 
rescued participant s, data after the rescue would be excluded from the analysis.  
See Section 9.4.3  for detail s on the exploratory efficacy objective based on PD parameters.  
Exploratory analyses may be performed for other PD parameters as deemed appropriate . 
 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  43 [IP_ADDRESS].  Pharmacokinetics  
[IP_ADDRESS].1.  Pharmacokinetic  Parameter Estimation  
Glucagon concentration data after NG administration will be analyzed using a population PK 
approach via nonlinear mixed -effects modeling with the NONMEM software  due to limited 
number of PK samples collected in this study . Model -estimated population PK parameters will 
be reported. Additional population PK analysis may be performed by [CONTACT_730013].  
Evaluable P K outcome  is defined as having at least 1 postbaseline measure.  For rescued 
participant s, data after the rescue would be excluded from the analysis.  
9.4.3.  Exploratory Endpoint : Efficacy  
PG levels will be measured prior to the administration of glucagon, as well as at various time 
points after administration (SoA, Section 1.3), and may be used to assess efficacy of NG.  
Efficacy of NG will be assessed in terms of “treatment success .” This is defined as an increase of 
PG ≥20 mg/dL (1.11 mmol/L) from baseline within [ADDRESS_997058] completed the study, participant enrollment will be paused and a n interim 
analysis will be conducted, evaluating the data relating to the primary and secondary objectives  
(Section 9.4). 
After this interim analysis, if there are no safety concerns , study enrollment will resume.  
The S AP will describe the planned int erim analyses in greater detail . 
9.6. Data Monitoring Committee  
Not applicable.  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  44 10. Supporting Documentation and Operational Considerations  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
 The investigator will be responsible for reporting cases of suspected child 
abuse and/or neglect according to local  regulations  including local  medical 
association  (e.g., American Academy of Pediatrics, EU Academy of 
Pediatrics) or Health Department guidelines ). 
 This study will be conducted in accordance with the protocol and with the 
following:  
○ Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences International Ethical Guidelines  
○ Applicable IC H GCP Guidelines  
○ Applicable laws and regulations  
 The protocol, protocol amendments, ICF, IB, and other relevant documents 
(e.g., advertisements) must be submitted to an IRB/IEC by [CONTACT_10998]/IEC  before the study is initiated.  
 Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
 The investigator wi ll be responsible for the following:  
o Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, 
policies, and procedures established by [CONTACT_1201]/IEC  
o Notifying the IRB/IEC of SAEs  (and/or unanticipated adverse device 
effect s) or other significant safety findings as required by [CONTACT_1744]/IEC 
procedures  
o Providing oversight of the conduct of the study at the site and 
adherence to requirements of 21 Code of Federal Regulations , ICH 
guidelines, the IRB/IEC, European regulation 536/2014 for clinical 
studies (if applicable), and all other applicable local regulations  
 Investigator sites are compensated for participation in the study  as detailed in 
the clinical trial agreement . 
10.1.2.  Financial Disclosure  
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  45 certification or disclosure statements to the appropriate regulatory auth orities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study . 
10.1.3.  Informed Consent Process  
 The investigator or his/her representative will explain the nature  of the study , including 
the risks and benefits,  to the participant ’s parent /legal guardian  and answer all questions 
regarding the study.  
 The p articipant ’s parent/legal guardian  must be informed that participation in this study  is 
voluntary. The p articipant ’s legally acceptable representative,  parent , or legal 
guardian  will be required to provide a statement of informed consent that meets the 
requirements of [ADDRESS_997059] requirements, where applicable, and 
the IRB/IEC or study center.  
 The medical record must include a statement that  consent from the legally 
acceptable  representative, parent(s), or legal guardian was obtained before the partic ipant 
was enrolled in the study and the date the written consent was obtained. The medical 
record should also describe how the clinical investigator determined that the person 
signing the ICF was the participant’s legally acceptable  representative, parent( s), or legal 
guardian. The site staff obtaining the informed consent must also sign the ICF.   
 The p articipant ’s legally acceptable representative,  parent(s), or legal guardian  must be 
reconsented to the most current version of the ICF(s) during their child’s participation in 
the study.   
 A copy of the ICF(s) must be provided to the participant’s legally acceptable  
representative, parent(s), or legal guardian . 
Prior to rescreening, the legally acceptable  representative, parent(s), or legal guardian  must sign 
a new ICF prior to any further study procedures.  
Assent from study participants is not required due to the very young age of the participants.  
10.1.4.  Data Protection  
● Participants will be assigned a unique identifier by [CONTACT_456]. Any participant 
records , datasets , or samples  that are transferred to the sponsor will contain the 
identifier only; participant names or any information that would make the 
participant identi fiable will not be transferred.  
● The participant ’s legally acceptable  representative, parent(s), or legal guardian  
must be informed that the participant’s  personal study -related data will be used by 
[CONTACT_10999]. The level of disclosure 
must also b e explained to the legally acceptable  representati ve, parent(s), or legal 
guardian  who will be required to give consent for their data to be used as 
described in the informed consent .  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  46 ● The participant ’s legally acceptable  representative, parent(s), or legal guardian  
must be informed that the participant ’s medical records may be examined by 
[CONTACT_103083], by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
● The sponsor has processes in place to ensure data protection, information security , 
and data integrity.  These processes include appropriate contingency plan(s) for 
appropriate and timely response in the event of a data security breach.  
10.1.5.  Dissemination of Clinical Study Data  
The sponsor will disclose a summary of study information, including tabular study results, on 
publicly available websites where required by [CONTACT_51967].  
10.1.6.  Data Quality Assurance  
All participant data relating to the study will be recorded on eCRF unless transmitted to the 
sponsor or designee electronically (e .g., PK data). The investigator is responsible for verifying 
that data entries are accurate and correct by [CONTACT_46388].  
The investigator must maintain accurate source documentation that s upports all information 
entered in  the eCRF.  Source  data may include  laboratory  tests,  medical  records,  and clinical  
notes.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents.  
Monitoring details describing strategy (e .g., risk -based initiatives in operations and quality such 
as Risk Management and Mitigation Strategies and Analytical Risk -Based Monitoring), methods, 
responsibilities , and requirem ents, including handling of noncompliance issues and monitoring 
techniques are provided in the Monitoring Plan . 
The sponsor or designee is responsible for the data management of this study includin g quality 
checking of the data.  
The sponsor assumes account ability for actions delegated to other individuals (e .g., CRO). 
Study monitors will perform ongoing source data verification to confirm that data entered into 
the CRF by [CONTACT_730014], complete, and verifiable from source documents; 
that the safety and rights of participants are being protected; and that the study is being 
conducted in accordance with the currently approved protocol and any other study agreements, 
ICH GCP, and all applicable regu latory requirements.  
Records and document s, including signed ICFs, pertaining to the conduct of this study must be 
retained by [CONTACT_730015] a longer retention period. No records may be 
destroyed during the retention period without the written approval of the sponsor. No records 
may be transferred to another location or party without w ritten notification to the sponsor . 
In addition, the sponsor  or its representatives will periodically check a sample of the participant  
data recorded against source documents at the study site.  The study may be audited by [CONTACT_730016] 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  47 sponsor  or its representatives , and/or regulatory agencies at any time.  Investigators will be given 
notice before an audit occurs.  
Data capture system  
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor . 
An electronic data capture system will be used in this study for the collection of CRF data.  The 
investigator maintains a separate source for the data entered by [CONTACT_52012] -provided electronic data capture  system.  The i nvestigator is responsible for the 
identification of any data to be considered source and for the confirmation that data reported are 
accurate and complete by [CONTACT_11003] . 
Data collected via the sponsor -provided data capture system(s)  will be  stored at  a third  party. The 
investigator will have continuous access to the data during the study and until decommissioning 
of the data capture system (s). Prior to decommissioning, the investigator will receive an archival 
copy of pertinent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system and reports  will be provided to the investigator for review 
and retention.  Data will subsequently be transferred from the central vendor to the sponsor  data 
warehouse.  
Data from complaint forms submitted to the sponsor  will be encoded and stored in the global 
product complaint management system.  
10.1.7.  Source Documents  
Source documents are defined in Section 10.1.6 . 
● Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documen ts are filed at the 
investigator’s site.  
● Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies 
must be explained. The investigator may need to request previous medical records 
or transfer records, depending on the study. Also, current medical records must be 
available.  
10.1.8.  Study and Site Start and Closure  
The study start date is the date on which the clinical study will be open for recruitment of 
participants.  
The sponsor designee reserves the right to close the study site or terminate the study at any time 
for any reason at the sole discretion of the sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of t he intended termination.  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  48 Reasons for the early closure of a study site by [CONTACT_11004]  
● failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities,  the sponsor ’s procedures, or GCP guidelines  
● inadequate recruitment of participants by [CONTACT_093]  
● discontinuation of further study intervention development  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the  
investigators, the IECs/IRBs, the regulatory authorities, and any CRO (s) used in the study of the 
reason for termination or suspension, as specified by [CONTACT_1214]. The 
investigator shall promptly inform the participant ’s parent /legal guardian , and assure appropriate 
participant  therapy and/or follow -up. 
10.1.9.  Publication Policy  
In accordance with the sponsor’s publication policy, the results of this study will be submitted 
for publication by a peer -reviewed journal if the results are deemed to be of significant medical 
importance.  
10.1.10.  Investigator Information  
Physicians with experience  in pediatric  clinical studies, and in treating pediatric patients  with 
diabetes , will participate as investigators in this clinical trial.   
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  49 10.2. Appendix 2: Clinical Laboratory Tests  
The following tests will be performed by [CONTACT_12082] . 
● Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 5 of the protocol.  
● Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_11006].  
Investigators must document their review of each labo ratory safety report.   
Safety Laboratory Tests  
Hematology  Clinical Chemistry  
Hematocrit  Sodium  
Hemoglobin  Potassium  
Erythrocyte count (RBC)  Chloride  
Mean cell volume  Glucose  
Mean cell hemoglobin  Blood urea nitrogen (BUN)  
Mean cell hemoglobin concentration  Albumin  
Leukocytes (WBC)  Total bilirubin  
Platelets  Alkaline phosphatase  (ALP)  
Differential WBC % of : Aspartate aminotransferase (AST)  
Neutrophils  Alanine aminotransferase (ALT)  
Lymphocytes  Creatinine  
Monocytes  Magnesium  
Eosinophils  Bicarbonate  
Basophils  Phosphorus  
 HbA1 c 
Abbreviations : HbA1c  = glycated hemoglobin; RBC = red blood cell; WBC = white blood cell.  
 
  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  50 10.3. Appendix 3: Adverse Events: Definitions , and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
10.3.1.  Definition of AE  
AE Definition  
 An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study intervention, whether or no t considered 
related to the study intervention.  
 NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study intervention .  
 
Events Meeting  the AE D efinition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (e .g., electrocardiogram , radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator (i .e., not related to 
progression of underlying disease).  
 Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in  frequency and/or intensity of the condition.  
 New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/s elf-harming 
intent. Such overdose should be reported regardless of sequelae.  
 The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be 
reported as an AE or SAE if they fulfil l the definition of an AE  or SAE. Also, “ lack of 
efficacy ” or “ failure of expected pharmacological action ” also constitutes an AE or 
SAE.  
 
Events NOT  Meeting the AE D efinition  
 Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the under lying disease, unless judged by [CONTACT_11009]’s condition.  
 The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  51  Medical or surgical procedure (e .g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admiss ion to a hospi[INVESTIGATOR_307]).  
 Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.   
10.3.2.  Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (e .g., hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to 
progression of disease).  
An SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term ‘life-threatening ’ in the definition of ‘serious ’ refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.  
c. Requ ires inpatient hospi[INVESTIGATOR_1081]  
 In general, hospi[INVESTIGATOR_597970]/or treatment that would not have been appropriate in the 
physician’s off ice or outpatient setting. Complications that occur during hospi[INVESTIGATOR_10911]. If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
neces sary, the AE should be considered serious.  
 Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.  
d. Results in persistent disability/incapacity  
 The term disability means a substantial dis ruption of a person’s ability to conduct 
normal life functions.  
 This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (e .g., sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption . 
e. Is a congenital anomaly/birth defect  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  52 f. Other situations:  
 Medical or scientific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may not be 
immediately life  threatening or result in death or hospi[INVESTIGATOR_729990] 1 of the other 
outcomes listed in the above definition. These events should usually be considered 
serious.  
 Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, bloo d dyscrasias , or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or 
drug abuse . 
10.3.3.  Recording and Follow -Up of AE and/or SAE  
AE and SAE Recording  
 When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e .g., hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics 
reports) related to the event.  
 The investigator will then record all relevant AE/SAE information in the CRF.  
 It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the sponsor or designee  in lieu of completion of the AE/SAE CRF page.  
 There may be instances when copi[INVESTIGATOR_61499] . In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copi[INVESTIGATOR_61500] . 
 The investigator will attempt to establish a d iagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE . 
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to 1 of the following categories:   
 Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort , 
and not interfering with everyday activities.  
 Moderate: An even t that causes sufficient discomfort and interferes with normal 
everyday activities.  
 Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with a n SAE. Severe is a category utilized for rating the  
intensity of an event; and both AEs and SAEs can be assessed as severe.  
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  53  
Assessment of Causalit y 
 The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.  
 The investigator  will consider  any AEs,  SAEs,  and clinically  important  laboratory  
abnormalities  as related  to the study  intervention  unless  there  is clear  evidence  that the 
event  is not related.  
 The investigator will use clinical judgment to determine the relationship.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal  relationship of the event to study intervention 
administration will be considered and investigated.  
 The investigator will also consult the IB and/or Product Information, for marketed 
products, in his/her assessment.  
 For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
 There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor  or designee . 
However, it is very important that the investigator always make an assessment of 
causality for every event before the initial transmission of the SAE data to the sponsor 
or designee . 
 The investigator may change his/her opi[INVESTIGATOR_729991] -up 
information and send a n SAE follow -up report with the updated causality assessment.  
 The causality assessment is 1 of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -up of AEs and SAEs  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_730017]/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care professionals.  
 If a participant dies during participation in the study or during a recognized follow -up 
period,  the investigator will provide  the sponsor or designee  with a copy of any 
postmortem findi ngs including histopathology.  
 New or updated information will be recorded in the originally completed CRF.  
 The investigator will submit any updated SAE data to  the sponso r or designee  within 
24 hours of receipt of the information.  
 
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  54 10.3.4.  Reporting of SAEs  
SAE Reporting via Paper CRF  
 Facsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to the  sponsor or designee . 
 Initial notification  via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.  
 Contacts for SAE reporting can be found in  the SAE Report . 
  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  55 10.4. Appendix 4: Liver Safety: Suggested Actions and Follow -up 
Assessments  
At the PI’s discretion, in the event  of suspected hepatic impairment  of a study participant , close 
or comprehensive monitoring may be conducted . 
Close hepatic monitoring  
Laboratory tests (Appendix 2, Section 10.2), including ALT, AST, ALP, TBL, as well as direct 
bilirubin , gamma glutamyltransferase , and creatine kinase , should be conducted.  
These should be repeated within 48 to 72  hours to confirm the abnormality and to determine if it 
is increasing or decreasing, if 1 or more of these conditions occur:  
If a participant with baseline results of ...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN  
ALP <1.5x ULN  ALP ≥2x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for patients with Gilbert’s syndrome)  
  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥2x baseline (except for patients with Gilbert’s syndrome)  
If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation for 
possible causes of abnormal liver tests should be initiated by [CONTACT_61520] -designated medical monitor. At a minimum, this eva luation should include physical 
examination and a thorough medical history, including symptoms, recent illnesses ( e.g., heart 
failure, systemic infection, hypotension, or seizures), recent travel, history of concomitant 
medications (including over -the-coun ter), herbal and dietary supplements, history of alcohol 
drinking and other substance abuse.  
Initially, monitoring of symptoms and hepatic biochemical tests should be done at a frequency of 
1 to 3 times weekly, based on the participant’s clinical conditio n and hepatic biochemical tests. 
Subsequently, the frequency of monitoring may be lowered to once every 1 to 2 weeks, if the 
participant’s clinical condition and lab oratory  results stabilize. Monitoring of ALT, AST, ALP, 
and TBL should continue until level s normalize or return to approximate baseline levels.  
Comprehensive hepatic evaluation   
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
one or more of these conditions occur:  
If a participant with baseline 
results of...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN with hepatic signs/symptoms*, or  
ALT or AST ≥5x ULN  
ALP <1.5x ULN  ALP ≥3x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for patients with Gilbert’s syndrome)  
  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline with hepatic signs/symptoms*, or 
ALT or AST ≥3x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  56 TBL ≥1.5x ULN  TBL ≥1.5x baseline (except for patients with Gilbert’s syndrome)  
 * Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, and/or 
eosinophilia >5%.  
At a minimum, this evaluation should include physical examination and a thorough medical 
history, as outlined above, as well as tests for prothrombin time -international normaliz ed ratio; 
tests for viral hepatitis A, B, C, or E; tests for autoimmune hepatitis; and an abdominal imaging 
study ( e.g., ultrasound or computed tomography  scan).  
Based on the participant ’s histor y and initial results, further testing should be considered in 
consultation with the Lilly -designated medical monitor, including tests for hepatitis D virus, 
cytomegalovirus, Epstein -Barr virus, acetaminophen levels, acetaminophen protein adducts, 
urine to xicology screen, Wilson’s disease, blood alcohol levels, urinary ethyl glucuronide, and 
serum phosphatidylethanol. Based on the circumstances and the investigator’s assessment of the 
participant’s clinical condition, the investigator should consider referr ing the participant for a 
hepatologist or gastroenterologist consultation, magnetic resonance cholangiopancreatography, 
endoscopic retrograde cholangiopancreatography, cardiac echocardiogram, or a liver biopsy.   
Additional hepatic data collection (hepatic safety CRF) in study participants who have 
abnormal liver tests during the study  
Additional hepatic safety data collection in hepatic safety CRF should be performed in study 
participants who meet 1 or more of the following 5 conditions:  
1. Elevation of serum  ALT level to ≥5x ULN on 2 or more consecutive blood tests (if 
baseline ALT <1.5x ULN)  
➢ In participants with baseline ALT level ≥1.5x ULN, the threshold is ALT  level  
≥3x baseline on 2 or more consecutive tests  
2. Elevat ion of  TBL level to ≥2x ULN (if baseline TBL level <1.5x ULN) (except for cases 
of known Gilbert ’s syndrome)  
➢ In participants with baseline TBL level ≥1.5x ULN, the threshold should be TBL 
level ≥2x baseline  
3. Elevation of serum ALP level to ≥2x ULN on 2 or more consecutive blood te sts (if 
baseline ALP <1.5x ULN)  
➢ In participants with baseline ALP level ≥1.5x ULN, the threshold is ALP level 
≥2x baseline on 2 or more consecutive blood tests  
4. Hepatic event considered to be a n SAE  
5. Discontinuation of study drug due to a hepatic event  
Note : the interval between the  consecutive blood tests should be at least 2 days.  
 
  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  57 10.5. Appendix 6: Blood Sampling Summary  
The following table  summarizes the approximate  number of venipunctures and blood volumes 
for all blood sampling (screening, safety laboratories , and bioanalytical assays) during the  study.  
Protocol I8R -MC-IGBO Sampling Summary for full sampling  
 
Purpose  Blood Volume per 
Sample (mL)  Number of Blood 
Samples  Total Volume 
(mL)  
Screening chemistry and 
hematologya 3 1 3 
Bedside point -of-care glucose 
monitoring b - 9 0.01 
Pharmacokinetics ( plasma 
glucagon)  2 3 6 
Pharmacodynamics ( plasma 
glucose)  0.[ADDRESS_997060] for cannula patency  1 5 5 
Total    14.51  
Total for clinical purposes [rounded up to the nearest 10 mL]  20 
a Additional  samples may be drawn if needed for safety purposes.   
b Applies only to  participants for whom a point -of-care blood glucometer  will be used, i.e. , this is not needed for 
participants who are  using their own continuous glucose monitoring equipment (see Sect ion [IP_ADDRESS] ). The v olume 
of each glucose measurement using a point -of-care blood glucometer  is estimated at  0.3 to 1.5 µL (0.0003 to 
0.0015  mL; ADA 2020 ). 
  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  58  
10.6. Appendix 7: Abbreviations  
Term  Definition  
AE adverse event  
ALP alkaline  phosphatase  
ALT alanine aminotransferase  
AST aspartate aminotransferase  
AUC  area under the concentration -time curve  
BG blood glucose  
BGmax  maximum observed BG  
CGM  continuous glucose monitoring  
complaint  A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug de livery system.  
compliance  Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.  
CRF case report form  
CRO  contract research organization  
CRP  clinical research physician:  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician,  clinical research 
scientist, global safety physician , or other medical officer.  
eCRF  electronic case report form  
enroll  The act of assigning a participant  to a treatment.  Participants  who are enrolled in the 
study are those who have been assigned to a treatment.  
enter  Participants  entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.  
GCP  good clinical practice  
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  59 informed consent  A process by [CONTACT_9444] a participant , or their parent or legal guardian,  voluntarily confirms 
their willingness to participate in a particular study, after having been informed of all 
aspects of the study that are relevant to the decision to participate.  Informed consent is 
documented by [CONTACT_3553] a written, signed , and dated i nformed consent form . 
interim analysis  An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.  
investigational 
product  A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.  
IRB Institutional Review Board  
ISPAD  International Society for Pediatric and Adolescent Diabetes  
IV intravenous  
MDI multiple daily injection  
NG nasal glucagon  
participant  Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_10930] a control  
PG plasma glucose  
PI [INVESTIGATOR_433667]/PD  pharmacokin etics/pharmacodynamics  
SAE serious adverse event  
SAP statistical analysis plan  
SC subcutaneous  
screen  The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.  
SoA schedule of activities  
T1D type [ADDRESS_997061] upper limit of normal  
  
Approved on 28 Jul 2022 GMT
CONFIDENTIAL  I8R-MC-IGBO (a) 
  60 11. References  
Abraham  MB, Jones TW, Naranjo D, et al. ISPAD Clinical Practice Consensus Guidelines 2018: 
assessment and management of hypoglycemia in children and adolescents with diabetes. 
Pediatr Diabetes . 2018;19(Suppl. 27):178 -192. https://doi.org/10.1111/pedi.[ZIP_CODE]  
[ADA ] American Diabetes Association. Diabetes Forecast 2020 consumer guide – meters. 
Accessed March 15, 2021 . http://main.diabetes.org/dforg/pdfs/2020/2020 -cg-blood -glucose -
meters.pdf?utm_sourc e=Offline&utm_medium=Print&utm_content=meters&utm_campaign=
DF&s_src=vanity&s_subsrc=meters  
Baqsimi  [LOCATION_002] Package Insert [USPI]. Indianapolis, IN: Eli Lilly and Company; 20 20. 
Accessed March 15, 2021 . http://pi.lilly.com/us/baqsimi -uspi.pdf  
Calpol Saline Nasal Sp ray Product Information Leaflet  [PIL] . Dublin : [COMPANY_012] 
(Ireland) Ltd ; 2010 . Accessed  March 15, 2021 . 
https://www.boots.com/wcsstore/ExtendedSitesCatalogAssetStore/Product_PatientLeaflets/A0
0000322 -10097250.P -Calpol_S&C_Saline_Nasal_Spray.pdf  
Children’s Nasacort  [USPI ]. Paris, [LOCATION_009]: [COMPANY_011] SA ; 2015.  Accessed  March 15, 2021 . 
https://dailymed.nlm.nih.gov/d ailymed/drugInfo.cfm?setid=2683ce6a -c4d2 -4d51 -9bb6 -
d842581ebdd8  
DiMeglio  LA, Acerini CL, Codner E, et al. ISPAD Clinical Practice Consensus Guidelines 2018: 
glycemic control targets and glucose monitoring for children, adolescents, and young adults 
with di abetes. Pediatr Diabetes.  2018 ;19(Suppl 27):105 -114. 
https://onlinelibrary.wiley.com/doi/full/10.1111/pedi.[ZIP_CODE]  
Graf CJ, Woodworth JR, Seger ME, et al. Pharmacokinetic and glucodynamic comparisons of 
recombinant and animal -source glucagon after IV, IM, and SC injection in healthy volunteers. 
J Pharm Sci . 1999;88(10):991 -995. https://doi.org/ 10.1021/js99007p  
Jones  TW. De fining relevant hypoglycemia measures in children and adolescents with type 1 
diabetes.  Pediatr Diabetes . 2018;19(3):354 -355. doi:10.1111/pedi.[ZIP_CODE]  
Narcan  Nasal Spray  [PIL]. Plymouth Meeting, PA: Adapt Pharma Inc ; 2020. Accessed March 
15, 2021 . https://da ilymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=724df050 -5332 -4d0a -
9a5f-17bf08a547e1&audience=professional  
OraVerse  [USPI ]. Louisville, CO: Septodont  Inc; 2018. Accessed March 15, 2021 . 
https://www.drugs.com/pro/oraverse.html  
Sterimar  Blocked Nose Baby [PIL]. Levallois Perret, [LOCATION_009]: Sofibel SAS; 2019. Accessed 
March 15, 2021. https://www.laboratoribaldacci.it/wp -content/uploads/2019/02/Foglietto -
illustrativo_Sterimar -Baby.pdf  
Approved on 28 Jul 2022 GMT
Signature [CONTACT_11032]-CLIN-069838 v1.0
Signature [CONTACT_11032]-CLIN-069838 v1.0Approval
Medical Director
28-Jul-2022 14:43:40 GMT[PHONE_006]
Approval
Statistician
28-Jul-2022 17:20:54 GMT[PHONE_006]
Approved on 28 Jul 2022 GMT
[COMPANY_003]
[COMPANY_003]